Celldex Therapeutics, Inc. - Common Stock (CLDX)
20.93
-0.43 (-2.01%)
NASDAQ · Last Trade: Apr 29th, 6:44 PM EDT
Via Benzinga · April 28, 2025
Via Benzinga · March 20, 2025

Via Benzinga · February 28, 2025

Via Benzinga · January 29, 2025

Via Benzinga · December 20, 2024

Via Benzinga · November 20, 2024

Via Benzinga · February 18, 2025

Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.
Via Benzinga · January 8, 2025

Via Benzinga · September 27, 2024

Via Benzinga · September 25, 2024

Via Benzinga · September 9, 2024

CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 9, 2024

Via Benzinga · July 30, 2024

Via Benzinga · July 30, 2024

Via Benzinga · July 30, 2024

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
Via Benzinga · July 28, 2024

CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 6, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via Benzinga · March 1, 2024